Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1053233 | 0.84 | GAA (0.58) | GAANPC1RAB9AMGLLSMN1; SMN2 | |
| SCHEMBL28217739 | 0.84 | NPC1 (0.62) | GAANPC1RAB9AMGLLSMN1; SMN2 | |
| SCHEMBL28114044 | 0.82 | GAA (0.57) | GAANPC1RAB9AMGLLSMN1; SMN2 | |
| SCHEMBL3644384 | 0.81 | GAA (0.49) | GAANPC1RAB9AMGLLSMN1; SMN2 | |
| SCHEMBL3642475 | 0.81 | GAA (0.49) | GAANPC1RAB9AMGLLSMN1; SMN2 | |
| SCHEMBL4636570 | 0.79 | GAA (0.54) | GAANPC1RAB9AMGLLSMN1; SMN2 | |
| SCHEMBL11882343 | 0.79 | MGLL (0.72) | GAANPC1RAB9AMGLLSMN1; SMN2 | |
| SCHEMBL28785029 | 0.77 | GAA (0.73) | GAANPC1RAB9AMGLLSMN1; SMN2 | |
| SCHEMBL1587673 | 0.77 | GAA (0.59) | GAANPC1RAB9AMGLLSMN1; SMN2 | |
| SCHEMBL27076411 | 0.76 | GRIN1 (0.52) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115583-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2025-04-10 | — | — | US | disclosed |
| US-12098141-B2 | Bicyclic indazole glucocorticoid receptor antagonists | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-09-24 | — | — | US | disclosed |
| EP-3856735-B1 | FUSED BICYCLIC HETEROCYCLES AS THERAPEUTIC AGENTS | UNIV NEW YORK (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20230242514-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115583-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, NR1I2 | GAA 4676/4885NPC1 1893/4885RAB9A 4839/4885 |
| US-12098141-B2 | Bicyclic indazole glucocorticoid receptor antagonists | NR3C1, NR3C2, NR1I2 | GAA 4676/4885NPC1 1893/4885RAB9A 4839/4885 |
| US-20230242514-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, NR1I2 | GAA 4676/4885NPC1 1893/4885RAB9A 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.